F 0759
Ensure medication error rates are not 5 percent or greater.
Level of Harm - Minimal harm
or potential for actual harm
Based on observation of medication pass, staff interview, medical record review, review of manufacturer's
instructions, review of medication card instructions and review of facility policy, the facility failed to maintain
a medication error rate of less than five percent. The facility medication error rate was calculated to be
10.34 percent (%) and included three medication errors of 29 observed medication opportunities. This
affected two residents (#58 and #75) of four residents observed for medication pass. The facility census
was 96.
Residents Affected - Few
Findings include:
1. Review of the medical record for the Resident #58 revealed an admission date of 01/04/22. Diagnoses
included cerebral infarction (stroke), dementia, syncope (fainting), type II diabetes, chronic kidney disease
and depression.
Review of the September 2024 physician orders revealed an order for potassium chloride extended release
(ER) 20 milliequivalent (meq) by mouth, vitamin C 50 milligram (mg), ferrous sulfate 325 mg, losartan 25
mg and a multivitamin.
Observation on 09/18/24 at 8:40 A.M. of medication pass with Licensed Practical Nurse (LPN) #250
revealed LPN #250 prepared Resident #58's morning medications, including the potassium chloride ER.
Resident #58 requested LPN #250 cut the pill in half due to difficulty swallowing. Resident #58 was unable
to swallow the potassium chloride ER. LPN #250 then crushed the potassium chloride ER, mixed the
crushed medication in pudding and administered the crushed potassium chloride ER to Resident #58.
Interview on 12/08/20 at 8:51 A.M. with LPN #250 verified she crushed the potassium chloride ER and
administered the crushed medication to Resident #58. LPN #250 stated the pill was scored and able to be
crushed. LPN #250 stated she called the pharmacy about crushing potassium for another resident and was
told potassium could be crushed.
Review of the manufacture's prescribing instructions for potassium chloride ER revealed the formulation
was intended to slow the release of potassium so the likelihood of a high localized concentration of
potassium chloride within the gastrointestinal tract is reduced. Potassium chloride ER tablets are to be
swallowed whole without crushing, chewing or sucking the tablets.
2. Review of the medical record for Resident #75 revealed an admission date of 01/04/24. Diagnoses
included chronic kidney disease, heart failure, anxiety disorder, peripheral vascular disease, hypothyroidism
and constipation.
Review of the September 2024 physician orders revealed morning medications included levothyroxine
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 2
Event ID:
365811
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
365811
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
09/24/2024
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Northwestern Healthcare Center
570 North Rocky River Drive
Berea, OH 44017
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0759
Level of Harm - Minimal harm
or potential for actual harm
(used to treat hypothyroidism) 50 microgram (mcg) by mouth in the morning, simethicone (used to treat
flatulence) 80 mg, Eliquis (anticoagulant) 2.5 mg, aspirin 81 mg, carvedilol (used to treat high blood
pressure) 6.25 mg, clopidogrel (used to treat heart problems) 75 mg, gabapentin (used to treat pain) 100
mg losartan 50 mg and omeprazole (used to treat gastroesophageal reflux) 40 mg. Instructions included
resident requests not to receive medication before 8:00 A.M.
Residents Affected - Few
Observation of medication pass on 09/19/24 at 8:30 A.M. with Medication Technician (MT) #240 revealed
the MT prepared levothyroxine and simethicone, along with seven additional medications, and administered
the medications to Resident #75. Review of the levothyroxine medication card revealed instructions to give
the medication on an empty stomach and four hours after receiving an antacid, iron and/or simethicone.
Concurrent interview with Resident #75 revealed he had breakfast, including a muffin and cereal,
proportionately 20 minutes prior to his medications being administered.
Interview on 09/19/24 at 8:45 A.M. with MT #240 revealed she administered Resident #75's medications
based on his preference. MT #240 stated she was unaware levothyroxine was to be given on an empty
stomach and should not be administered with simethicone.
Review of the manufactures prescribing instructions for levothyroxine revealed the medication should be
administered on an empty stomach, one-half hour to one hour before breakfast, and administer at least four
hours before or after drugs that are known to interfere with absorption, including simethicone.
Review of the facility policy titled Medication Administration, undated, revealed follow manufacture's
recommendations for medications that note do not crush.
This deficiency represents noncompliance investigated under Complaint Number OH00157286 and
Complaint Number OH00157231.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
365811
If continuation sheet
Page 2 of 2